Professor Jens K. Habermann, M.D., PhD, is the Director-General of BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium) since September 2020. For his current position at BBMRI-ERIC, the University of Lübeck has granted him a leave of absence in official and public interest from his occupancies as Head of the Section of Translational Surgical Oncology and Biobanking and as Head of ICB-L (Interdisciplinary Center for Biobanking-Lübeck). Prof. Habermann obtained his M.D. training at the Medical University of Lübeck (Lübeck, Germany), received his PhD at the Cancer Center Karolinska, Karolinska Institute (Stockholm, Sweden) and a Postdoctoral Fellowship at the National Cancer Institute, NIH (Bethesda, USA).

As a board certified specialist in human genetics, Prof. Habermann combines clinics, biobanking, and translational (cancer) research to optimize precision medicine. Prof. Habermann was actively involved in the Molecular Tumor Board as part of the precision medicine program in Lübeck and a member of the Ethics Board of the University of Lübeck. Prof. Habermann was President of ESBB (European, Middle Eastern & African Society for Biopreservation & Biobanking; esbb.org) from 2018 to 2020 and board member of GBN/GBA (German Biobank Node and German Biobank Alliance; BBMRI.de).

Prof. Habermann received more than 15 scientific awards, holds about 10 patents and patent applications, is a reviewer and editorial board member of more than 25 scientific journals and member of numerous scientific societies. He has translational cancer research and biobanking related publication track record and was the principal investigator and co-PI in more than 21 national and European grant projects.